Abstract
Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 704-716 |
| Number of pages | 13 |
| Journal | Nature Reviews Immunology |
| Volume | 9 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2009 |
Bibliographical note
Funding Information:C.H.J. is grateful for support by the US National Institutes of Health (NIH) (grants 5R01CA105216, 1R01CA120409, 5P01CA066726 and 1U19AI082628) and the Alliance for Cancer Gene Therapy. B.R.B. acknowledges direct support of this work by the US NIH (grants 2R01HL56067, R01AI34495, R01CA72669, P01CA142106 and P01AI056299) as well as a Leukemia and Lymphoma Translational Research Award. J.L.R. receives support from the US NIH (grants P30AI045008, R01AI057838, R01CA113783, R41CA130547, U19AI066290, U19AI082628 and P01AI080192) as well as from the JDRF Center on Cord Blood Therapies for Type 1 Diabetes.
